UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 21.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 83,074 shares of the company’s stock after selling 22,839 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.18% of Pacira BioSciences worth $1,250,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in PCRX. Pacer Advisors Inc. lifted its stake in Pacira BioSciences by 129.4% in the 3rd quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company’s stock valued at $74,681,000 after buying an additional 2,799,434 shares in the last quarter. Fort Washington Investment Advisors Inc. OH purchased a new stake in shares of Pacira BioSciences in the 2nd quarter valued at approximately $13,240,000. Assenagon Asset Management S.A. raised its holdings in shares of Pacira BioSciences by 314.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 553,114 shares of the company’s stock valued at $8,324,000 after buying an additional 419,656 shares during the period. Doma Perpetual Capital Management LLC grew its holdings in shares of Pacira BioSciences by 71.8% in the second quarter. Doma Perpetual Capital Management LLC now owns 1,000,761 shares of the company’s stock valued at $28,632,000 after purchasing an additional 418,321 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Pacira BioSciences by 269.7% during the third quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock worth $5,955,000 after purchasing an additional 288,662 shares in the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Barclays decreased their target price on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 12th. Jefferies Financial Group lifted their target price on shares of Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. HC Wainwright reiterated a “buy” rating and set a $39.00 target price on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Royal Bank of Canada boosted their price objective on shares of Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Pacira BioSciences in a report on Friday, November 8th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Pacira BioSciences currently has an average rating of “Hold” and a consensus target price of $23.50.

Pacira BioSciences Trading Down 0.2 %

Pacira BioSciences stock opened at $19.83 on Wednesday. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $35.95. The stock has a 50-day moving average price of $17.44 and a 200 day moving average price of $18.82. The stock has a market cap of $915.61 million, a PE ratio of -9.77 and a beta of 0.80. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.